VBWG - Resource Item

Resources

Quick Order
About Create Profile Login
Email: Password:

Slide Lecture Programs
2007 Core Curriculum cash advance cash advance
Contemporary Management of Cardiometabolic Risk cash advance cash advance
May 15, 2007
Table of Contents - 105 slides
No.	Title
1	Contemporary Management of Cardiometabolic Risk cash advance cash advance
2	A continuing epidemic: 2 of 3 US adults are overweight or obese cash advance cash advance
3	Parallel epidemics of diabetes and obesity cash advance cash advance
4	Defining cardiometabolic risk cash advance cash advance
5	Associations of adiposity with CVD cash advance cash advance
6	Adiposity predicts mortality cash advance cash advance
7	Adiposity associated with premature MI cash advance cash advance
8	Majority of patients undergoing PCI are overweight or obese cash advance cash advance
9	Adverse consequences of chronic adiposity and ectopic fat cash advance cash advance
10	Epicardial adipose tissue may be increased in visceral obesity cash advance cash advance
11	Adiposity in the development of NASH cash advance cash advance
12	Visceral vs subcutaneous adiposity cash advance cash advance
13	Neutral effect of liposuction on cardiometabolic risk factors cash advance cash advance
14	Central adiposity: Better marker of CVD than BMI cash advance cash advance
15	A new vital sign: Waist circumference cash advance cash advance
16	Continued burden of disease cash advance cash advance
17	Adiposity in CVD cash advance cash advance
18	Role of adipose tissue in atherogenesis cash advance cash advance
19	Elevated FFA contribute to hypertension, dyslipidemia, and insulin resistance cash advance cash advance
20	Energy homeostasis is linked to immune balance cash advance cash advance
21	Weight gain induces inflammatory changes in adipose tissue cash advance cash advance
22	Adipose tissue: An endocrine organ cash advance cash advance
23	Adiponectin associated with decreased risk of MI cash advance cash advance
24	Beneficial associations of adiponectin cash advance cash advance
25	Low adiponectin in visceral adiposity cash advance cash advance
26	Even moderate weight loss may improve cardiometabolic risk cash advance cash advance
27	Summary cash advance cash advance
28	The Endocannabinoid System cash advance cash advance
29	Cannabinoid classification with selected examples cash advance cash advance
30	ECS: Widely distributed with multiple cardiometabolic effects cash advance cash advance
31	Potential therapeutic implications of CB₁ receptor blockade cash advance cash advance
32	Circulating 2-AG elevated in persons with visceral vs sc adiposity cash advance cash advance
33	CB₁ receptor blockade blunts overeating in rats cash advance cash advance
34	CB₁ receptor blockade: Weight reduction independent of food intake in obese mice cash advance cash advance
35	CB₁ receptor blockade modulates adipocyte function in mice cash advance cash advance
36	CB₁ receptors modulate liver lipogenesis in mice cash advance cash advance
37	CB₁ receptor blockade increases skeletal muscle glucose uptake in obese mice cash advance cash advance
38	CB₁ receptor blockade and mood: Range of effects observed in animal models cash advance cash advance
39	Endocannabinoid system overview cash advance cash advance
40	Managing Cardiometabolic Risk cash advance cash advance
41	NHLBI guidelines: Adiposity assessment cash advance cash advance
42	BMI classifications cash advance cash advance
43	Measuring waist circumference cash advance cash advance
44	Diagnostic criteria for metabolic syndrome cash advance cash advance
45	NHLBI guidelines: Weight loss goals cash advance cash advance
46	Guide to adiposity management cash advance cash advance
47	NHLBI guidelines: Lifestyle modification cash advance cash advance
48	Some moderate-intensity physical activities cash advance cash advance
49	3-Week diet + exercise regimen yields favorable metabolic changes cash advance cash advance
50	Physical activity may reduce CV and all-cause mortality cash advance cash advance
51	Lifestyle modification associated with diabetes prevention cash advance cash advance
52	DPP: Benefit of diet + exercise or metformin on diabetes prevention in at-risk patients cash advance cash advance
53	Popular dietary programs: Effective yet difficult to maintain cash advance cash advance
54	Look AHEAD: Study design cash advance cash advance
55	NHLBI guidelines: Pharmacologic therapy cash advance cash advance
56	Pharmacologic weight management options cash advance cash advance
57	Efficacy of orlistat as adjunct to lifestyle modification cash advance cash advance
58	Efficacy of sibutramine as adjunct to lifestyle modification cash advance cash advance
59	Effects of sibutramine and lifestyle modification on cardiometabolic risk factors cash advance cash advance
60	SCOUT: Study design cash advance cash advance
61	NHLBI guidelines: Weight loss surgery cash advance cash advance
62	SOS: Bariatric surgery-associated improvements in cardiometabolic risk cash advance cash advance
63	Improved Framingham risk score following bariatric surgery cash advance cash advance
64	Clinical evaluation of CB₁ receptor blockade cash advance cash advance
65	Rimonabant In Obesity (RIO) program cash advance cash advance
66	RIO program: Improved cardiometabolic risk factors at 1 year cash advance cash advance
67	RIO program: Decreased metabolic syndrome incidence cash advance cash advance
68	RIO program: Safety and tolerability cash advance cash advance
69	RIO program: No significant effect on mood cash advance cash advance
70	RIO program: Mood at 1 year cash advance cash advance
71	RIO clinical trial program efficacy summary cash advance cash advance
72	SERENADE: Study design cash advance cash advance
73	SERENADE: Change in A1C at 6 months cash advance cash advance
74	Summary cash advance cash advance
75	Ongoing trials with rimonabant in abdominal adiposity cash advance cash advance
76	Current and emerging pharmacologic combinations for treating cardiometabolic risk cash advance cash advance
77	Managing cardiometabolic risk cash advance cash advance
78	Data Supplement cash advance cash advance
79	RIO-Europe: Study design cash advance cash advance
80	RIO-Europe: Treatment effect on weight and waist circumference cash advance cash advance
81	RIO-Europe: Treatment effect on lipids cash advance cash advance
82	RIO-Europe: Adverse events cash advance cash advance
83	RIO-Lipids: Study design cash advance cash advance
84	RIO-Lipids: Treatment effect on weight and WC cash advance cash advance
85	RIO-Lipids: Treatment effect on lipids cash advance cash advance
86	RIO-Lipids: Rimonabant weight-independent effect on adiponectin cash advance cash advance
87	RIO-Lipids: Adverse events cash advance cash advance
88	RIO-Diabetes: Study design cash advance cash advance
89	RIO-Diabetes: Treatment effect on weight and waist circumference cash advance cash advance
90	RIO-Diabetes: Treatment effect on lipids cash advance cash advance
91	RIO-Diabetes: Treatment effect on glucose metabolism cash advance cash advance
92	RIO-Diabetes: Adverse events cash advance cash advance
93	RIO-North America: Study design cash advance cash advance
94	RIO-North America: Weight change by treatment assignment cash advance cash advance
95	RIO-North America: Waist circumference by treatment assignment cash advance cash advance
96	RIO-North America: Treatment effect on lipids at 1 year cash advance cash advance
97	RIO-North America: Weight-independent and weight-dependent effects on lipids cash advance cash advance
98	RIO-North America: Weight-independent and weight-dependent effects on insulin and IR cash advance cash advance
99	RIO-North America: Adverse events cash advance cash advance
100	RIO-North America: Adverse events, cont'd cash advance cash advance
101	Obesity program depression-related events: Overall incidences cash advance cash advance
102	Completed phase 2 and 3 studies as of March 2007: All suicidality-related events cash advance cash advance
103	Rimonabant clinical safety: Summary cash advance cash advance
104	ACOMPLIA: European product information cash advance cash advance
105	ACOMPLIA: European product information, cont'd cash advance cash advance


Home \| Literature Update \| Journal Link \| Resources \| Meeting Highlights \| Members \| About VBWG \| Web Links